News Archive

2021

May

Media Release / May 28, 2021

Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program

Read More
Media Release / May 26, 2021

Novartis commits to addressing racial disparities in breast cancer screening, treatment and care

Read More
Media Release / May 01, 2021

Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

Read More

April

Media Release / Apr 23, 2021

Novartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in children with moderate to severe plaque psoriasis

Read More
Media Release / Apr 16, 2021

Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS

Read More
Media Release / Apr 16, 2021

Novartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosis

Read More
Media Release / Apr 12, 2021

Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

Read More

March

Media Release / Mar 17, 2021

Novartis awards $450,000 to eight nonprofit organizations through the STEP Program™

Read More

February

Media Release / Feb 16, 2021

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Read More

January

Media Release / Jan 15, 2021

Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic idiopathic urticaria (CIU)

Read More

Related Links